Tempus AI (TEM) Soars 15% on $1.1-Billion Deal

We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday.

Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in sealed contracts and achieving a revenue retention of around 126 percent last year.

At market close, the stock finished 4.51 percent at $69.26 apiece.

In a statement, Tempus AI Inc. (NASDAQ:TEM) said that it inked data agreements with 70 customers last year, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, as well as biotechnology companies namely Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics, among others.

“2025 was a record year for our Data and applications business—both from a revenue and TCV perspective,” said Tempus AI Inc. (NASDAQ:TEM) Chief Finance Officer Jim Rogers.

“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond,” he added.

Tempus AI Inc. (NASDAQ:TEM) said that official data from its 2025 financial and operating performance have yet to be finalized, but said that it targets to announce the results in an earnings call in February 2026.

While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.